B+
Bull case
20%
Probability
Target price
$68.00
Analysis reference price unavailable
Analysis 2026-02-06 · RankAlpha Sentiment AI
BMY
Bristol-Myers SquibbCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$57.68
Analysis reference price unavailable
Analysis 2026-02-06 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$37.00
Analysis reference price unavailable
Analysis 2026-02-06 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-02-06
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+46.7
Score
AI commentary
Market consensus is broadly neutral-to-slightly-bearish with median targets near $57.68 while the anchor price trades at $59.51, indicating limited upside in the near term [#SERP-8] [#SERP-4]. Coverage shows a wide spread between low and high analyst views, reflecting binary pipeline and litigation risks [#SERP-3].
RankAlpha Sentiment AI - 2026-02-06
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-07catalystQuarterly earnings and updated 2026 guidanceMedium impact
Q4/FY2025 earnings release and management guidance update; market reaction likely if EPS/revenue or guidance diverges from consensus [#SERP-4]. Date conservatively estimated to allow filings and call prep.
2026-12-31eventLate-stage clinical readout / regulatory milestone (assumed window end)High impact
Potential Phase III readout or regulatory decision for a late-stage oncology/immunology asset; date uses conservative window end assumption and may move shares materially if outcome differs from expectations [#SERP-1]. Assumed window end for planning.
2027-02-06catalystPatent, litigation or portfolio M&A developmentsHigh impact
Potential litigation outcomes, biosimilar decisions, or strategic M&A that could re-rate valuation over a multi-quarter horizon; date set conservatively one year out [#SERP-2].
Recommendation
N/A
No formal recommendation provided.
As of 2026-02-06 • Updated nightlySource: Internal modelMethodology